Amlexanox
Amlexanox (small-molecule TBK1/IKK-epsilon inhibitor; not a peptide)
Evidence grade 2 of 5, Thin. Read how the Atlas grades evidence.
Amlexanox is a small-molecule drug, not a peptide, and its evidence splits sharply by use. For its long-standing approved indications (recurrent aphthous ulcers as Aphthasol 5% oral paste in the US, and asthma/allergic rhinitis as Solfa in Japan) it carries decades of clinical use and would grade higher for those uses. For the experimental TBK1/IKK-epsilon repurposing in obesity and type 2 diabetes, the human record is a single small phase 2 (NCT01975935, 42 randomized, 12 weeks, 50 mg three times daily), which met its HbA1c endpoint with roughly a 0.5% mean advantage but showed effects that were strongly responder-dependent (7 of 20 treated patients reached the responder threshold). That places the metabolic/fat-loss use, which is what this library entry markets, at grade 2 (preliminary human), not higher.
- FDA
- FDA-approved as Aphthasol 5% oral paste for recurrent aphthous ulcers (1997), since discontinued in the US; metabolic/obesity use is investigational only
- WADA
- Not listed on the WADA Prohibited List
Reference only. Not medical advice.
What can go wrong
For the experimental metabolic use, human data are limited to one small 12-week phase 2 with responder-dependent effects and transient IL-6 elevation; the approved oral-paste use is generally well tolerated with local application-site reactions.
Amlexanox is a small-molecule anti-inflammatory drug (not a peptide) that is FDA-approved as Aphthasol 5% oral paste for canker sores and marketed in Japan as Solfa for asthma and allergic rhinitis. The obesity and type 2 diabetes repurposing, based on its inhibition of the kinases TBK1 and IKK-epsilon in the Saltiel lab, reached only a single small phase 2 trial with modest, responder-dependent metabolic effects, which is the experimental use grouped with fat-loss peptides in community protocols.
What people take it for
These are the reasons people give for taking it. They are not effects it has been shown to have.
How it is supposed to work
This entry pairs amlexanox, a repurposed anti-inflammatory drug, with AOD-9604, a fragment of growth hormone marketed for fat loss. Amlexanox inhibits two inflammation-related enzymes (IKK-epsilon and TBK1) that, when overactive in obesity, are thought to lock in a low-metabolism, insulin-resistant state; blocking them may modestly restore metabolic rate and insulin sensitivity. AOD-9604 was designed to trigger fat breakdown without growth-hormone side effects. The combination is a gray-market fat-loss stack rather than a studied drug.
Amlexanox is a small-molecule drug, not a peptide, developed in the 1980s and long used for aphthous ulcers and, abroad, asthma and allergic rhinitis. Its metabolic action comes from inhibiting two related inflammatory enzymes, IKK-epsilon and TBK1.
- Type
- Small-molecule drug, NOT a peptide
- Origin
- Asthma and canker-sore drug
- Target
- IKK-epsilon and TBK1
- Human data
- Yes, modest
- Benefit
- Mainly an inflamed subset
- Metabolic approval
- None
Not A Peptide, But An Old Drug Repurposed For Metabolism, Helping A Subset
Amlexanox has one of the more grounded stories among the compounds sold alongside peptides, with the honest caveats being who it helps and that it is not a peptide. It is an old drug with a long, favorable safety record, repurposed through real target-driven science: researchers studying the link between inflammation and obesity found that two inflammatory enzymes, IKK-epsilon and TBK1, are elevated in the obese state and suppress energy expenditure, then screened roughly a hundred fifty thousand chemicals for inhibitors and landed on amlexanox. Blocking those enzymes in obese mice produced weight loss, better insulin sensitivity and less fatty liver. Unusually for the compounds in this library, it also has genuine human trial data, not just mouse: in a placebo-controlled study of obese type 2 diabetics, it significantly lowered blood-sugar markers. The decisive honesty is in the detail. The clear benefit, including improved insulin sensitivity and reduced fatty liver, appeared mainly in a subset of responders identifiable by a high-inflammation signature in their fat, not in everyone, and amlexanox is not approved for obesity or diabetes. Its approvals are for canker sores and asthma; the metabolic use is investigational repurposing that has not advanced to approval.
Safety in detail
This entry describes a small-molecule drug, not a peptide. The approved use (canker-sore paste, and asthma/rhinitis in Japan) is well characterized, while the fat-loss/metabolic use promoted in community protocols rests on a single small phase 2 and remains investigational.
- Amlexanox has an established safety record in its approved anti-inflammatory uses, with generally mild effects.
- Its metabolic benefit in obesity was modest and limited to a subgroup, not a proven weight-loss therapy.
- AOD-9604 failed its obesity trials, so the fat-loss rationale for the combination is weak.
- Combined gray-market use is unstudied, and research-chemical quality is unverified.
- Neither is approved for weight loss.
Children and teenagers
Amlexanox’s metabolic use has no validated pediatric basis and is unapproved; any use in minors should be limited to its approved indications under medical care.
What people get wrong
Nothing recorded here yet. There is almost certainly something people get wrong about this one, and the blank space means we have not written it down, not that the record is clean.
Who profits, and who pushes back
Nobody is named here yet, because we have not done that work on this entry. Read that as unfinished. Somebody almost certainly sells this, and somebody almost certainly disputes it. Assume both until we have checked.
Amlexanox has a conventional approved market for canker sores and, abroad, asthma, and reaches metabolic users through gray-market and compounding channels and off-label discussion. Its metabolic future would depend on further trials and an obesity or diabetes approval that has not materialized.
How we got here
Amlexanox originated in Japan under the developmental code AA-673 and was first approved there in the 1980s as Solfa for bronchial asthma and allergic rhinitis, with related brands such as Aftach and Elics used for oral and allergic indications. Its US rights were developed for a different purpose, treatment of recurrent aphthous ulcers, with the use patent assigned to Chemex Pharmaceuticals and FDA approval of the 5% oral paste as Aphthasol reaching the market in 1997, a product later discontinued in the US. A separate and much newer chapter began when Alan Saltiel's laboratory identified amlexanox as an inhibitor of the inflammatory kinases TBK1 and IKK-epsilon (Nature Medicine, 2013), prompting metabolic repurposing that carried it into a single small phase 2 obesity/diabetes trial; that experimental metabolic role, not any approved indication, is what has drawn it into fat-loss peptide community protocols despite it being a small molecule.
Amlexanox was developed in the 1980s in Japan for asthma and allergic rhinitis and later used for canker sores. In the 2010s, University of Michigan and UC San Diego researchers studying inflammation and obesity identified its inflammatory-enzyme targets and repurposed it, showing metabolic benefit in mice and a modest, subset-dependent blood-sugar effect in a human trial, without advancing to metabolic approval.
The numbers behind the grade
- Type
- Anti-inflammatory + GH fragment
- Amlexanox
- IKKe/TBK1 inhibitor
- AOD-9604
- Failed obesity trials
- Approved (weight loss)
- No
- Evidence
- Modest/limited
- Use
- Gray-market stack
The people taking it
A niche metabolic-and-fat-loss stack built on an interesting anti-inflammatory mechanism and a fat-loss fragment whose own trials disappointed.
Amlexanox’s metabolic users are fat-loss and metabolic-health seekers drawn to its repurposing story, particularly those with inflammatory metabolic disease, alongside its conventional users treating canker sores.
Used gray-market as a fat-loss and metabolic stack; amlexanox has real but modest metabolic data and approved anti-inflammatory uses, while the AOD-9604 component is unproven for weight loss.
Set against the alternatives
Amlexanox is grouped with the metabolic compounds it is sold beside, the proven drug Semaglutide as a contrast, the metabolic peptide 5-Amino-1MQ and the mitochondrial peptide MOTS-c, and it shares the non-peptide outlier role with SLU-PP-332. Its distinction is having real human trial data, unusual here, paired with the honest limit that the benefit is concentrated in an identifiable inflamed subgroup rather than universal.
What we do not know
- Whether amlexanox’s anti-inflammatory metabolic effect can be developed into a real obesity treatment.
- Whether pairing it with a failed fat-loss fragment adds anything.
- Which patients, if any, the inflammation-targeting approach actually helps.
Legal status
Amlexanox is approved as an anti-inflammatory in some markets but not for weight loss; AOD-9604 is not approved and failed its obesity trials. The combination is a gray-market and compounded fat-loss stack, not an evidence-based therapy.
Status current as of July 2026. Regulatory positions change, sometimes quickly.
The market for this
What follows describes how this is bought and sold. It is not a buying guide and it is not an endorsement of any seller.
Amlexanox is available as an approved anti-inflammatory in some markets by prescription; the fat-loss combination is sold through compounding or gray-market vendors and is not an evidence-based weight-loss product. Proven options for weight loss lie elsewhere.
Amlexanox exists as an approved drug in some markets; the fat-loss combination is assembled through compounding and gray-market research-chemical supply, the latter with the usual quality caveats.
What this entry does not yet cover
What follows is unfinished work on our side, not a finding about Amlexanox.
- Timeline. We have not built the dated record of research and regulatory events.
- Supply chain. We have not mapped where it is made.
- What could change. No forward-looking summary yet.
Sources
Amlexanox 5% oral paste (Aphthasol) is FDA-approved for aphthous ulcers; dosing four times daily
Phase 2 RCT: 42 obese type 2 diabetics, 12 weeks, HbA1c reduced ~0.5% vs placebo, responder-dependent
Same phase 2 trial, publisher record confirming design and outcomes
Amlexanox inhibits TBK1/IKK-epsilon and reverses obesity-related metabolic dysfunction in mice (mechanistic basis)
Mouse mechanism, PubMed record of the Nature Medicine 2013 study
Chemistry: 2-amino-7-isopropyl-chromeno[2,3-b]pyridine carboxylic acid, C16H14N2O4, a small molecule; US drug discontinued
First approved in Japan in the 1980s as Solfa for asthma and allergic rhinitis; US Aphthasol history
Aphthasol 5% is the only FDA-approved prescription drug for aphthous stomatitis; well tolerated, anti-inflammatory/anti-allergic
Randomized placebo-controlled dental trial of amlexanox for recurrent aphthous stomatitis (approved-use evidence)
Amlexanox characterized as a selective TBK1/IKK-epsilon inhibitor reagent
The studies that matter
Amlexanox metabolic trial (Oral et al, Cell Metabolism)2017
A small trial in obese patients with type 2 diabetes found amlexanox produced modest weight loss and improved blood sugar in a subset with higher inflammation, a genuine but limited metabolic signal.
Amlexanox approved usesestablished
Amlexanox is an approved anti-inflammatory in some markets (for canker sores, and for asthma in Japan), so it has a real safety history, just not for weight loss.
AOD-9604 obesity trials2000s
AOD-9604 failed to beat placebo for weight loss in its Phase 2/3 obesity program, undercutting the fat-loss half of the combination.